Lars Tögel
Scientist
John M. Mariadason Lab Ludwig Center at Melbourne
Ludwig Institute for Cancer Research
Australia
Biography
A hallmark of tumor development is aberrant cell signaling. In 50% of all colon cancers the MAPK/ERK signaling pathway is constitutively activated because of mutations in the proto-oncogenes KRAS or BRAF. Whether negative feedback regulators of this pathway also need to be overcome to facilitate constitutive signaling through this pathway, and the mechanisms by which this might occur, are unknown. My research is focused on elucidating the genetic and epigenetic mechanism that leads to the repression of negative feedback regulators of MAPK/ERK signaling in colon cancer, with a particular focus on DUSP5.
Research Interest
Oncogenic transcription, tumor development, cell signalling, BRAF
Publications
-
Chueh, Anderly C., et al. "Mechanisms of histone deacetylase inhibitor-regulated gene expression in cancer cells." Antioxidants & redox signaling 23.1 (2015): 66-84.
-
Wilson, Andrew J., et al. "Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction." Cancer research 70.2 (2010): 609-620.
-
Waithman, Jason, et al. "Resident CD8+ and migratory CD103+ dendritic cells control CD8 T cell immunity during acute influenza infection." PLoS One 8.6 (2013): e66136.
